Yuan et al. show that SETD2 methylates EZH2 and promotes its degradation in prostate cancer. Unmethylated EZH2 due to SETD2 deficiency or a SETD2 mutation causes epigenetic reprogramming and promotes metastasis. Metformin induces SETD2 through AMPK-FOXO3, highlighting a link between metabolism and epigenetics.
from Cancer Cell https://ift.tt/31JCP4J
from Cancer Cell https://ift.tt/31JCP4J